Topics:

DaunoXome Is Recommended for Approval for Kaposi's Sarcoma

DaunoXome Is Recommended for Approval for Kaposi's Sarcoma

BOULDER, Colo--NeXstar Pharmaceuticals, Inc. has announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) has recommended approval of DaunoXome, NeXstar's liposomal formulation of daunorubicin, as first-line therapy for Kaposi's sarcoma. ODAC made its recommendation upon review of the company's amended NDA, which included data from NeXstar's phase III study of 227 HIV-positive patients with advanced Kaposi's sarcoma.

 
Loading comments...
Please Wait 20 seconds or click here to close